Figures & data
Table 1. Characteristics of eligible trials
Figure 1. Diagram of risk of bias summary and bias graph for the 9 eligible studies
Figure 1. Continued
Figure 2. Flow diagram of study selection for the current meta-analysis
Figure 3. (a,b). Seroconversion rate (SCR) at day 21 post-vaccination, QIV versus TIV in adults between 18 and 64 years old (A strains). (SCR is defined as the percentage of participants with either a pre-vaccination HAI titer <10 and a post-vaccination HAI titer ≥40 or a pre-vaccination HI titer ≥10 and a ≥4-fold increase in HI titer after vaccination)
Figure 3. Continued
Figure 4. (a,b). Seroprotection rate (SPR) at day 21 post-vaccination, QIV versus TIV in adults under 65 years old. (SPR is defined as the percentage of participants with a HAI titres≥40)
Figure 4. Continued
Figure 5. Local and systemic adverse events(AE) post vaccination, QIV versus pooled TIV (TIV groups combined TIV-B/Victoria & TIV-B/Yamagata)
